MICHAEL GESCHWIND
Estados Unidos
Dr. Michael Geschwind is a Professor of Neurology at the University of California, San Francisco. His primary areas of clinical research are in rapidly progressive dementias (RPDs; including prion diseases and antibody-mediated encephalopathies), Huntington’s disease, spinocerebellar ataxias and atypical parkinsonian disorders. He and his team run an active clinical research program in sporadic and genetic prion disorders. Dr. Geschwind helped run the first ever treatment trial for sporadic Jakob-Creutzfeldt disease (sJCD) in the United States. Over the past 16 years, he has helped recruit one of the largest clinical cohorts in the United States of patients with prion disease, as well as patients with other non-prion RPDs. His team has been following more than 100 families with genetic prion disease. Dr. Geschwind also is involved clinically in caring for patients with mild cognitive impairment, Alzheimer’s disease, frontotemporal dementia, Huntington’s disease, CADASIL and other adult-onset leukoencephalopathies, atypical Parkinsonian dementias and various neurogenetic disorders.
Estados Unidos
Dr. Michael Geschwind is a Professor of Neurology at the University of California, San Francisco. His primary areas of clinical research are in rapidly progressive dementias (RPDs; including prion diseases and antibody-mediated encephalopathies), Huntington’s disease, spinocerebellar ataxias and atypical parkinsonian disorders. He and his team run an active clinical research program in sporadic and genetic prion disorders. Dr. Geschwind helped run the first ever treatment trial for sporadic Jakob-Creutzfeldt disease (sJCD) in the United States. Over the past 16 years, he has helped recruit one of the largest clinical cohorts in the United States of patients with prion disease, as well as patients with other non-prion RPDs. His team has been following more than 100 families with genetic prion disease. Dr. Geschwind also is involved clinically in caring for patients with mild cognitive impairment, Alzheimer’s disease, frontotemporal dementia, Huntington’s disease, CADASIL and other adult-onset leukoencephalopathies, atypical Parkinsonian dementias and various neurogenetic disorders.